Gene Therapy Equipment
-
Manufactured by Lamellar Biomedical Ltdbased in UNITED KINGDOM
The active agent within LAMELLASOME™ IPF-NA balances the regulation of fibrosis within the ...
-
Manufactured by ViennaLab Diagnostics GmbHbased in AUSTRIA
NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI ...
-
Manufactured by ViennaLab Diagnostics GmbHbased in AUSTRIA
for clinical trials). Testing of patients with metastatic melanoma or advanced non-small cell lung cancer for BRAF V600 mutations prior to treatment is recommended, as BRAF V600 mutation positive patients may benefit from BRAF inhibitor therapy (e.g. dabrafenib, trametinib, ...
-
Manufactured by ViruSure GmbHbased in AUSTRIA
Gene therapy has brought hope to many diseases with unmet clinical need. The potential to permanently cure the patient through replacement of a defective gene with a healthy gene underscores the surge of interest in this exciting biopharma ...
-
based in USA
ImmTOR has significant potential to mitigate unwanted immune responses and induce AAV-specific tolerance to enable redosing of gene therapies. ImmTOR has the potential to administer multiple low doses to achieve therapeutic benefit without risk of overdosing, the ability to treat patients typically excluded from these ...
-
Manufactured by AVROBIO, Inc.based in USA
AVROBIO’s investigational gene therapy for cystinosis is being studied in a Phase 1/2 investigational trial sponsored by the University of California, San Diego. The first patient was dosed in October 2019. The single-arm trial is expected to enroll four adults and a potential follow-on cohort of two adults or adolescents at least 14 ...
-
Manufactured by Obsidian Therapeutics, Inc.based in USA
Engineered with membrane-bound IL15, Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy, Drives improved persistence, IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® ...
-
Manufactured by Gyroscope Therapeutics Limitedbased in UNITED KINGDOM
Our investigational gene therapy, GT005, is designed to restore balance to a part of our immune system called the complement ...
-
Manufactured by Clearside Biomedicalbased in USA
We believe our platform offers the potential for safer, targeted ocular gene therapy without some of the risks of surgery and subretinal administration. Suprachoroidal administration of gene therapy could ultimately enhance access to care because it does not require specialized gene therapy ...
-
Manufactured by AVROBIO, Inc.based in USA
AVROBIO has a preclinical research program for a gene therapy for Pompe disease. We have shown a favorable preclinical safety and efficacy profile in a mouse model of Pompe ...
-
Manufactured by Ocugen, Inc.based in USA
OCU410 (AAV-RORA) is a modifier gene therapy product candidate being developed for the treatment of dry age-related macular degeneration (Dry AMD). OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. Various genes associated with AMD are regulated by RORA. The RORA ...
-
Manufactured by Ocugen, Inc.based in USA
OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases (“IRDs”). It consists of a functional copy of a nuclear hormone receptor (“NHR”) gene, NR2E3, ...
-
Manufactured by AVROBIO, Inc.based in USA
AVROBIO’s investigational gene therapy for Fabry disease is currently being studied in two clinical trials. An investigator-sponsored Phase 1 trial in Canada is fully enrolled, with five patients dosed. Nine treatment-naïve patients have been dosed in the FAB-GT Phase 2 trial, which continues to enroll in Australia, the U.S. and ...
-
Manufactured by Zhejiang Tailin Bioengineering Co., Ltd.based in CHINA
Design based on stringent GMP aseptic production requirements and meets the requirements of various regulatory agencies (FDA, EMA, NMPA) regulations and industry guidelines (ISO, PDA, USP, Chinese ...
-
Manufactured by Unchained Labsbased in USA
Stunner is the only system that pulls together UV/Vis concentration, Dynamic Light Scattering (DLS) and Static Light Scattering (SLS) data from the same 2 μL sample. Dig in to your AAV to get the total capsid titer and empty/full ratio, or rack up payload concentration and size data on any nanoparticle all at once. Nail down your protein quality by knocking concentration, hydrodynamic size, ...
-
Manufactured by Holostem Terapie Avanzate S.r.l.based in ITALY
Epidermolysis Bullosa (EB) is a group of genetic adhesion disorders characterized by fragility of the skin. EB are devastating, highly disfiguring, blistering pathologies that severely impairs the quality of life of patients and affect approximately 500,000 people worldwide ...
-
Manufactured by IGEA S.P.A.based in ITALY
Incorporates a commercial syringe housing, guiding the injection to the centre of the electroporation volume. Easy control of needle insertion depth, as needles remain in the guide. Option to inject to different depths. Mechanical retraction of the syringe with a special trigger before ...
-
Manufactured by Eyevensysbased in FRANCE
EYS606 is a novel non-viral gene therapy approach that was developed for the treatment of chronic non-infectious uveitis (CNIU). CNIU, which meets the criteria for a rare disease (affecting 250,000 patients in North America and Europe), is a sight-threatening immune-mediated inflammatory disease that causes inflammation in the eye that can ...
-
Manufactured by Eyevensysbased in FRANCE
Innovative drug delivery platform turns the eye into a biofactory. Our proprietary technology enables the eye to generate its own therapeutic proteins. Our novel non-viral gene therapy platform turns the eye into a production site for sustained delivery of therapeutic proteins by introducing proprietary DNA plasmids encoding therapeutic ...
-
Manufactured by AVROBIO, Inc.based in USA
AVROBIO’s investigational gene therapy for Gaucher disease is being studied in a Phase 1/2 clinical trial to evaluate the safety and efficacy in individuals with Gaucher disease type 1. The trial is now enrolling in Canada, Australia and the U.S. The trial is intended to recruit 8 to 16 individuals between the ages of 16 and 35 with ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you